Patent intelligence · DK
DK 2928905
FREMGANGSMÅDE TIL OPRENSNING AF TERAPEUTISKE PROTEINER
FREMGANGSMÅDE TIL OPRENSNING AF TERAPEUTISKE PROTEINER
Patent details — DK 2928905
- Jurisdiction
- DK
- Status
- granted
- Grant date
- Mar 11, 2019
- Expiration
- Mar 6, 2039
- Applicant
- CSL BEHRING GMBH [DE]
- CPC classes
- A61K/3836, A61K/3837
Quick answer
DK 2928905 (FREMGANGSMÅDE TIL OPRENSNING AF TERAPEUTISKE PROTEINER) is held by CSL BEHRING GMBH [DE]. Status: granted. Granted Mar 11, 2019. Expires Mar 6, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CSL BEHRING GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/3836, A61K/3837
More from CSL BEHRING GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2022258590
PROCÉDÉ D'ISOLEMENT DE PLASMINOGÈNE À PARTIR D'UNE FRACTION DE PLASMA SANGUIN
granted -
CA 3198740
METHODES DE TRAITEMENT D'UN REJET A MEDIATION PAR ANTICORPS
granted -
AU 2017305856
Pharmaceutical formulations of C1 esterase inhibitor
granted -
CA 3072003
PROCEDE DE FILTRATION VIRALE DU FACTEUR DE VON WILLEBRAND
granted -
US 2018264111
PHARMACEUTICAL PRODUCT WITH INCREASED STABILITY COMPRISING IMMUNOGLOBULINS
granted -
CA 3046406
PRODUIT DE REMPLACEMENT DE FACTEUR DE COAGULATION SANGUINE POUR UTILISATION DANS LE TRAITEMENT PROPHYLACTIQUE OU THERAPEUTIQUE DES HEMORRAGIES
granted -
CA 3034568
PROCEDE DE PREVENTION D'ATTAQUES AIGUES D'OEDEME DE QUINCKE HEREDITAIRE ASSOCIEES A UNE DEFICIENCE EN INHIBITEUR DE C1 ESTERASE
granted
Frequently asked questions
What is US patent 2928905?
DK 2928905 (FREMGANGSMÅDE TIL OPRENSNING AF TERAPEUTISKE PROTEINER) is held by CSL BEHRING GMBH [DE]. Status: granted. Granted Mar 11, 2019. Expires Mar 6, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns DK 2928905?
CSL BEHRING GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does DK 2928905 expire?
Our index shows an expiration date of Mar 6, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.